Dual‐Antigen‐Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications
Small · 2024
DOI: 10.1002/smll.202307748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Fangjie Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine Institute of Molecular Medicine, State Key Laboratory of Systems Medicine for Can…. Hauptthemen laut MEDLINE: Nanovaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Innovative Research Team of High-level Local University in Shanghai, Interdisciplinary Program of Shanghai Jiao Tong University.
Abstract (Originalsprache)
As one of the most common complications, infection causes the majority of mortality in cancer patients. However, therapeutic strategies that can simultaneously suppress tumors and protect patients from infection have been rarely reported. Here, the use of dual‐antigen‐displaying nanovaccines (DADNs) is described to elicit synergistic immunoactivation for treating cancer and preventing infectious complications. DADNs are prepared by wrapping immunoadjuvant‐loaded nanoparticles with a hybrid coating, which is fused from cell membranes that are separately genetically engineered to express tumor and infectious pathogenic antigens. Due to the presence of a dual‐antigen combination, DADNs are able to promote the maturation of dendritic cells and more importantly to trigger cross‐presentation of both combined antigens. During in vivo investigations, we find that DADNs can reverse immunosuppression by stimulating tumor‐associated antigen‐specific T‐cell responses, resulting in significantly delayed tumor growth in mice. These nanovaccines also elicit effective protective immunity against tumor challenges and induce robust production of pathogenic antigen‐specific immunoglobulin G antibody in a prophylactic study. This work offers a unique approach to develop dual‐mode vaccines, which are promising for synchronously treating cancer and preventing infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine Institute of Molecular Medicine, State Key Laboratory of Systems Medicine for Cancer Renji Hospital School of Medicine, Shanghai Jiao Tong University,…
- Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lun…
- College of Material, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Key Laboratory of Organosilicon Material Technology, Hangzhou Normal Uni…
- Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Department of Ophthalmology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200011, China.
ORCID-Profile: Lu Wang, Jinyao Liu
Förderung
- National Key Research and Development Program of China
- Innovative Research Team of High-level Local University in Shanghai
- Interdisciplinary Program of Shanghai Jiao Tong University
- Shanghai Sailing Program
- Shandong Provincial Natural Science Foundation
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Explorer Program of the Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Chen, F., Zhang, M., Yang, F., Wang, L., Liu, J., Liu, J., & Pang, Y. (2024). Dual‐Antigen‐Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications. Small. https://doi.org/10.1002/smll.202307748
Vancouver
Chen F, Zhang M, Yang F, Wang L, Liu J, Liu J, et al. Dual‐Antigen‐Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications. Small. 2024. doi:10.1002/smll.202307748
BibTeX
@article{Chen2024,
author = {Chen, Fangjie and Zhang, Mengmeng and Yang, Fengmin and Wang, Lu and Liu, Jinyao and Liu, Junqiu and Pang, Yan},
title = {Dual‐Antigen‐Displaying Nanovaccines Elicit Synergistic Immunoactivation for Treating Cancer and Preventing Infectious Complications},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202307748}
}
EUVIMED